Latigo Biotherapeutics Q2 Net Loss Narrows

05:04 PM EDT, 09/03/2026 (MT Newswires) -- Latigo Biotherapeutics (LTGO) reported a Q2 net loss late Thursday of $27.59 per diluted share, narrowing from a loss of $36.52 a year earlier. The company said its cash and cash equivalents were $55 million as of June 30, including the net proceeds from its initial public offering, and are expected to fund its current operating plans into 2029.